{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:16:27Z","timestamp":1761110187325},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","labmed.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.cll.2016.05.002","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T20:37:02Z","timestamp":1466023022000},"page":"461-472","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacogenetics in Oral Antithrombotic Therapy"],"prefix":"10.1016","volume":"36","author":[{"given":"Cheryl L.","family":"Maier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cll.2016.05.002_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.cll.2008.07.001","article-title":"Fundamentals of pharmacology and applications in pharmacogenetics","volume":"28","author":"Valdes","year":"2008","journal-title":"Clin Lab Med"},{"key":"10.1016\/j.cll.2016.05.002_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","article-title":"Inheritance and drug response","volume":"348","author":"Weinshilboum","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2016.05.002_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11239-006-5580-y","article-title":"Worldwide management of oral anticoagulant therapy: the ISAM study","volume":"21","author":"Pengo","year":"2006","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.cll.2016.05.002_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1021\/tx00025a009","article-title":"Hydroxylation of warfarin by human cDNAexpressed cytochrome P450: a role for P4502C9 in the etiology of warfarin drug interactions","volume":"5","author":"Rettie","year":"1992","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.cll.2016.05.002_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cll.2016.05.002_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00008571-199512000-00008","article-title":"Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy","volume":"5","author":"Furuya","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.cll.2016.05.002_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-008-0584-5","article-title":"Influence of CYP2C9 genotype on warfarin dose requirements- a systematic review and meta-analysis","volume":"65","author":"Lindh","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cll.2016.05.002_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature02214","article-title":"Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2","volume":"427","author":"Rost","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.cll.2016.05.002_bib9","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2016.05.002_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2008-01-134247","article-title":"A\u00a0genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose","volume":"112","author":"Cooper","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cll.2016.05.002_bib11","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","article-title":"A\u00a0genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principle genetic determinants of warfrain dose","volume":"5","author":"Takeuchi","year":"2009","journal-title":"PLoS Genet"},{"issue":"4","key":"10.1016\/j.cll.2016.05.002_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/blood-2015-02-627042","article-title":"Race influences warfarin dose changes associated with genetic factors","volume":"126","author":"Limdi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cll.2016.05.002_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenomic data","volume":"360","author":"Klein","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cll.2016.05.002_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.thromres.2015.01.018","article-title":"Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials","volume":"135","author":"Li","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.cll.2016.05.002_bib15","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K anatagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.cll.2016.05.002_bib16","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1161\/CIRCULATIONAHA.112.105908","article-title":"Guided antithrombotic therapy: current status and future research direction","volume":"126","author":"Fuster","year":"2012","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.cll.2016.05.002_bib17","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Shulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.cll.2016.05.002_bib18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cll.2016.05.002_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrd2622","article-title":"Dabigatran etexilate","volume":"7","author":"Eriksson","year":"2008","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.cll.2016.05.002_bib20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/dmd.113.054353","article-title":"Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis","volume":"42","author":"Laizure","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cll.2016.05.002_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor dabigatran in humans","volume":"36","author":"Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"13","key":"10.1016\/j.cll.2016.05.002_bib22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","article-title":"Genetic determinants of dabigatran plasma levels and their relation to bleeding","volume":"127","author":"Pare","year":"2013","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.cll.2016.05.002_bib23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2016.05.002_bib24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/dmd.113.053561","article-title":"Impact of endogenous esterace activity on in\u00a0vitro p-glycoprotein profiling of dabigatran etexilate in Caco-2 monolayuers","volume":"42","author":"Ishiguro","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cll.2016.05.002_bib25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1365-2125.2012.04218.x","article-title":"Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin","volume":"74","author":"Hartter","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cll.2016.05.002_bib26","unstructured":"New oral anticoagulant drugs dabigatran etexilate and rivaroxaban: influence of genetic factors in healthy volunteers. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01627665. Accessed January 1, 2016."},{"key":"10.1016\/j.cll.2016.05.002_bib27","unstructured":"Influence of ABCB1 polymorphisms on plasma concentrations of new oral anticoagulants in case of serious adverse events. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02103101. Accessed January 1, 2016."},{"issue":"11","key":"10.1016\/j.cll.2016.05.002_bib28","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9984","key":"10.1016\/j.cll.2016.05.002_bib29","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the clinical response to warfarin and edoxaban: findings from the randomized double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cll.2016.05.002_bib30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrcardio.2011.96","article-title":"The evolution of antiplatelet therapy in cardiovascular disease","volume":"8","author":"Yousuf","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cll.2016.05.002_bib31","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"27","key":"10.1016\/j.cll.2016.05.002_bib32","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.cll.2016.05.002_bib33","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","article-title":"Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions","volume":"109","author":"Undas","year":"2007","journal-title":"Blood"},{"issue":"9510","key":"10.1016\/j.cll.2016.05.002_bib34","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cll.2016.05.002_bib35","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jacc.2005.05.090","article-title":"Overestimation of platelet aspirin resistance detection by thromboelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation","volume":"46","author":"Tantry","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.cll.2016.05.002_bib36","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2174\/1381612822666151208122845","article-title":"Pharmacogenomics of oral antithrombotic drugs","volume":"22","author":"Storelli","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"7","key":"10.1016\/j.cll.2016.05.002_bib37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","volume":"126","author":"Jneid","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cll.2016.05.002_bib38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","article-title":"Central role of the P2Y12 receptor in platelet activation","volume":"113","author":"Dorsam","year":"2004","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.cll.2016.05.002_bib39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cll.2016.05.002_bib40","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2174\/138920010794233521","article-title":"Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability","volume":"11","author":"Ancrenaz","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.cll.2016.05.002_bib41","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1517\/14656566.9.16.2893","article-title":"Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development","volume":"9","author":"Angiolillo","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cll.2016.05.002_bib42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","article-title":"Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease","volume":"29","author":"Wallentin","year":"2008","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.cll.2016.05.002_bib43","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.cll.2016.05.002_bib44","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"},{"issue":"4","key":"10.1016\/j.cll.2016.05.002_bib45","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.105.007989","article-title":"Interaction of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450","volume":"34","author":"Rehmel","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.cll.2016.05.002_bib46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FJC.0b013e3181492209","article-title":"Increased active metabolite formation explains the greater platelet inhibtion with prasugrel compared to high-dose clopidogrel","volume":"50","author":"Payne","year":"2007","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"7","key":"10.1016\/j.cll.2016.05.002_bib47","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood-2006-04-013052","article-title":"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects","volume":"108","author":"Hulot","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.cll.2016.05.002_bib48","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.cll.2016.05.002_bib49","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1111\/j.1538-7836.2011.04409.x","article-title":"Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study","volume":"9","author":"Fontana","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"22","key":"10.1016\/j.cll.2016.05.002_bib50","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","article-title":"Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement","volume":"55","author":"Hochholzer","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.cll.2016.05.002_bib51","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/jth.12342","article-title":"The CYP2C19*17 variant is not independently associated with clopidogrel response","volume":"11","author":"Lewis","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2016.05.002_bib52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/clpt.2013.105","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update","volume":"94","author":"Scott","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cll.2016.05.002_bib53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1160\/TH13-01-0021","article-title":"Cytochrome P450 2B6 and 2C9 genotype polymorphism \u2013 a possible cause of prasugrel low responsiveness","volume":"110","author":"Franken","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cll.2016.05.002_bib54","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.jcin.2012.07.015","article-title":"CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome","volume":"5","author":"Cuisset","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"9749","key":"10.1016\/j.cll.2016.05.002_bib55","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis","volume":"376","author":"Mega","year":"2010","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.cll.2016.05.002_bib56","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmokinetic, pharmacodynamic, and clinical outcomes","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.cll.2016.05.002_bib57","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","article-title":"Impact of p-glycoprotein on clopidogrel absorption","volume":"80","author":"Taubert","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"22","key":"10.1016\/j.cll.2016.05.002_bib58","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.jacc.2011.11.068","article-title":"Influence of genetic polymorphisms on the effect of high and standard dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study","volume":"59","author":"Price","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.cll.2016.05.002_bib59","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","article-title":"Ticagrelor: pharmacokinetic, pharmacodynamic, and pharmacogenetic profile: an update","volume":"54","author":"Teng","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.cll.2016.05.002_bib60","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.110.032250","article-title":"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects","volume":"38","author":"Teng","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cll.2016.05.002_bib61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cll.2016.05.002_bib62","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/09537100903075324","article-title":"Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation ni patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3","volume":"20","author":"Storey","year":"2009","journal-title":"Platelets"},{"issue":"6","key":"10.1016\/j.cll.2016.05.002_bib63","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCGENETICS.110.958561","article-title":"First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET\/OFFSET and RESPOND genotype studies","volume":"3","author":"Tantry","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cll.2016.05.002_bib64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ahj.2014.03.010","article-title":"Polymorphism of the cystatin C gene in patients with acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes Study","volume":"168","author":"Akerblom","year":"2014","journal-title":"Am Heart J"},{"issue":"12_S","key":"10.1016\/j.cll.2016.05.002_bib65","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1016\/S0735-1097(14)60025-5","article-title":"Ticagrelor plasma levels but not clinical outcomes are associated with transporter and metabolism enzyme genetic polymorphisms","volume":"63","author":"Varenhorst","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cll.2016.05.002_bib66","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2217\/pme.13.106","article-title":"Genotype-guided use of oral antithrombotic therapy: a pharmacoeconomic perspective.","volume":"11","author":"Sweezy","year":"2014","journal-title":"Personalized Medicine"},{"key":"10.1016\/j.cll.2016.05.002_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.331","article-title":"Physician response to implementation of genotype-tailored antiplatelet therapy.","author":"Peterson","year":"2016","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.cll.2016.05.002_bib68","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1538-7836.2010.04063.x","article-title":"Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study","volume":"8","author":"Fontana","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2016.05.002_bib69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1538-7836.2009.03644.x","article-title":"Adenosine disphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel","volume":"8","author":"Gremmel","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.cll.2016.05.002_bib70","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1538-7836.2010.04180.x","article-title":"More on: adenosine disphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel","volume":"9","author":"Tidjane","year":"2011","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271216300324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271216300324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T19:53:29Z","timestamp":1656705209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271216300324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0272271216300324"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2016.05.002","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics in Oral Antithrombotic Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2016.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}